Healthy Skepticism Library item: 14156
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
Sales Through Retail Pharmacies (Twelve months to June 2008)
IMS Health 2008 Aug 13
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Retail_Drug_Monitor_June_2008.pdf
Abstract:
Sales Through Retail Pharmacies
(Twelve months to June 2008*)
NORTH AMERICA $223.7billion up 2%
United States $206.7billion up 1%
Canada $16.9billion up 6%
EUROPE (Top 5) $115.3 billion up 3%
Germany $34.8billion up 6%
France $31.1billion up 3%
United Kingdom $17.0billion down 1%
Italy $16.9billion up 0%
Spain $15.1billion up 6%
JAPAN (including hospitals) $63.5billion up 5%
LATIN AMERICA (Top 3) $23.6billion up 9%
Brazil $11.9billion up 10%
Mexico $8.7billion up 5%
Argentina $2.9billion up 20%
AUSTRALIA/NEW ZEALAND $7.9billion up 12%
The top 5 therapy classes at ATC3 level in the 12 months to June 2008 were:
1. C10A – Cholesterol & Triglyceride regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to June 2008 were:
1. Lipitor
2. Nexium
3. Plavix
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to June 2008 were:
1. Pfizer
2. GlaxoSmithKline
3. Novartis
4. Astrazeneca
5. Sanofi-Aventis
